Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Trial Profile

A 24-Week Multicenter, Randomized, Blinded, Parallel-Group Study Comparing the Efficacy and Safety of Ixekizumab to Guselkumab in Patients With Moderate-to-Severe Plaque Psoriasis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 21 Feb 2019

At a glance

  • Drugs Guselkumab (Primary) ; Ixekizumab (Primary)
  • Indications Plaque psoriasis
  • Focus Therapeutic Use
  • Acronyms IXORA-R
  • Sponsors Eli Lilly and Company
  • Most Recent Events

    • 26 Sep 2018 Planned End Date changed from 30 Dec 2019 to 12 Nov 2019.
    • 26 Sep 2018 Planned primary completion date changed from 22 Jul 2019 to 28 May 2019.
    • 10 Sep 2018 According to Eli Lilly media release, Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top